Logo image of RSLS

RESHAPE LIFESCIENCES INC (RSLS) Stock Fundamental Analysis

NASDAQ:RSLS - Nasdaq - US76090R3093 - Common Stock - Currency: USD

0.3097  -0.05 (-14.71%)

After market: 0.3099 +0 (+0.06%)

Fundamental Rating

3

Overall RSLS gets a fundamental rating of 3 out of 10. We evaluated RSLS against 190 industry peers in the Health Care Equipment & Supplies industry. RSLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RSLS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RSLS has reported negative net income.
In the past year RSLS has reported a negative cash flow from operations.
In the past 5 years RSLS always reported negative net income.
RSLS had a negative operating cash flow in each of the past 5 years.
RSLS Yearly Net Income VS EBIT VS OCF VS FCFRSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

RSLS's Return On Assets of -125.86% is on the low side compared to the rest of the industry. RSLS is outperformed by 86.32% of its industry peers.
RSLS has a Return On Equity of -475.25%. This is amonst the worse of the industry: RSLS underperforms 84.74% of its industry peers.
Industry RankSector Rank
ROA -125.86%
ROE -475.25%
ROIC N/A
ROA(3y)-213.94%
ROA(5y)-174.81%
ROE(3y)-525.31%
ROE(5y)-397.87%
ROIC(3y)N/A
ROIC(5y)N/A
RSLS Yearly ROA, ROE, ROICRSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K 2K 3K

1.3 Margins

Looking at the Gross Margin, with a value of 68.19%, RSLS is in the better half of the industry, outperforming 73.68% of the companies in the same industry.
RSLS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for RSLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5Y9.59%
RSLS Yearly Profit, Operating, Gross MarginsRSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

RSLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RSLS has been reduced compared to 1 year ago.
The number of shares outstanding for RSLS has been increased compared to 5 years ago.
There is no outstanding debt for RSLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RSLS Yearly Shares OutstandingRSLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100K 200K 300K 400K 500K
RSLS Yearly Total Debt VS Total AssetsRSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

RSLS has an Altman-Z score of -162.22. This is a bad value and indicates that RSLS is not financially healthy and even has some risk of bankruptcy.
RSLS's Altman-Z score of -162.22 is on the low side compared to the rest of the industry. RSLS is outperformed by 95.26% of its industry peers.
There is no outstanding debt for RSLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -162.22
ROIC/WACCN/A
WACC8.98%
RSLS Yearly LT Debt VS Equity VS FCFRSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.33 indicates that RSLS should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.33, RSLS is doing worse than 75.79% of the companies in the same industry.
A Quick Ratio of 0.60 indicates that RSLS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.60, RSLS is doing worse than 90.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.33
Quick Ratio 0.6
RSLS Yearly Current Assets VS Current LiabilitesRSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

RSLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.65%, which is quite impressive.
The Revenue for RSLS has decreased by -16.59% in the past year. This is quite bad
The Revenue has been decreasing by -0.95% on average over the past years.
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-204.61%
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y76.07%
Revenue growth 5Y-0.95%
Sales Q2Q%6.36%

3.2 Future

Based on estimates for the next years, RSLS will show a very strong growth in Earnings Per Share. The EPS will grow by 41.36% on average per year.
RSLS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.06% yearly.
EPS Next Y99.78%
EPS Next 2Y41.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.24%
Revenue Next 2Y16.06%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RSLS Yearly Revenue VS EstimatesRSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
RSLS Yearly EPS VS EstimatesRSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RSLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RSLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RSLS Price Earnings VS Forward Price EarningsRSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RSLS Per share dataRSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200

4.3 Compensation for Growth

A more expensive valuation may be justified as RSLS's earnings are expected to grow with 41.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.36%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RSLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RESHAPE LIFESCIENCES INC

NASDAQ:RSLS (4/17/2025, 8:00:02 PM)

After market: 0.3099 +0 (+0.06%)

0.3097

-0.05 (-14.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-13 2025-05-13
Inst Owners4.1%
Inst Owner Change0%
Ins Owners5.18%
Ins Owner Change0%
Market Cap3.49M
Analysts43.33
Price TargetN/A
Short Float %16.61%
Short Ratio0.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.59%
Min Revenue beat(2)-12.78%
Max Revenue beat(2)-10.4%
Revenue beat(4)0
Avg Revenue beat(4)-11.15%
Min Revenue beat(4)-12.78%
Max Revenue beat(4)-9.41%
Revenue beat(8)0
Avg Revenue beat(8)-10.55%
Revenue beat(12)0
Avg Revenue beat(12)-14.07%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.43
P/FCF N/A
P/OCF N/A
P/B 2.35
P/tB 2.35
EV/EBITDA N/A
EPS(TTM)-205.92
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.73
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.86%
ROE -475.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.19%
FCFM N/A
ROA(3y)-213.94%
ROA(5y)-174.81%
ROE(3y)-525.31%
ROE(5y)-397.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5Y9.59%
F-Score5
Asset Turnover1.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.33
Quick Ratio 0.6
Altman-Z -162.22
F-Score5
WACC8.98%
ROIC/WACCN/A
Cap/Depr(3y)17.25%
Cap/Depr(5y)28.26%
Cap/Sales(3y)1.41%
Cap/Sales(5y)4.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-204.61%
EPS Next Y99.78%
EPS Next 2Y41.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y76.07%
Revenue growth 5Y-0.95%
Sales Q2Q%6.36%
Revenue Next Year12.24%
Revenue Next 2Y16.06%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.44%
OCF growth 3YN/A
OCF growth 5YN/A